Agoracom Blog Home

Posts Tagged ‘stocks’

Democracy Labs uses Datametrex AI $DM.ca #Nexalogy Tech to Study #Coronavirus Misinformation

Posted by AGORACOM-JC at 7:35 AM on Thursday, March 12th, 2020
  • Announce that Democracy Labs successfully used Nexalogy’s technology to monitor #covid19 and #coronavirus to identify misinformation campaigns and Fake News
  • Democracy Labs is a US based organization providing a hub for ongoing technology and creative innovation that serves progressive campaigns and organizations at the national, state, and local levels.

TORONTO, March 12, 2020 — Datametrex AI Limited (the “Company” or Datametrex”) (TSXV: DM) (FSE: D4G) is pleased to announce that Democracy Labs successfully used Nexalogy’s technology to monitor #covid19 and #coronavirus to identify misinformation campaigns and Fake News. Democracy Labs is a US based organization providing a hub for ongoing technology and creative innovation that serves progressive campaigns and organizations at the national, state, and local levels. In addition to misinformation about Covid-19 DemLabs has also used Nexalogy tech to examine Islamophobia against U.S. Representative Rashida Tlaib.

Key takeaways:

  • 450,000 tweets analyzed from March 1st through 4th using hashtag #covid19
  • Russia Today suggested that the U.S.A. primaries be cancelled and was promoted by BOTS

Results of these campaigns can be found by clicking the attached links:

https://insights.nexalogy.com/democracy-labs-uses-nexalogy-tech-to-study-coronavirus-misinformation-b88ea13c4bed
https://nexalogy.com/insights/keep-an-eye-on-trolls-activity-and-report-harassment-to-twitter/

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

For further information, please contact:

Jeff Stevens
Email: [email protected]Phone: 647-777-7974

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

INTERVIEW: Datametrex $DM.ca – The Small Cap #A.I. Company Governments Use To Fight Fake News & Election Meddling

Posted by AGORACOM-JC at 5:01 PM on Wednesday, March 11th, 2020

Until now, investor participation in Artificial Intelligence has been the domain of mega companies and those funded by Silicon Valley.  Small cap investors can finally consider participating in the great future of A.I. through Datametrex AI (DM: TSXV) (Soon To Be Nexaology) who has achieved the following over the past few months:

  • Q3 Revenues Of $1.6 million,  an increase of 186%
  • 9 Month Revenues Of $2.56M an increase of 37%
  • Repeat Contracts Of $1M and $600,000 With Korean Giant LOTTE   
  • $954,000 Contract With Canadian Department of Defence To Fight Social Media Election Meddling
  • Participation In NATO Research Task Group On Social Media Threat Detection 

When a small cap Artificial Intelligence company is successfully deploying its technology with military and conglomerates, smart investors have to take a closer look.   That look can begin with our latest interview of Datametrex CEO, Marshall Gunter, who talks to us about the use of the Company’s Artificial Intelligence to discover and eliminate US Presidential election meddling.  The fake news isn’t just targeting candidates specifically, it also targets wedge issues such as abortion cases now before the US Supreme Court and even the Coronavirus.   Watch this interview on one of your favourite screens or hit play and listen to the audio as you drive. 

The most expensive #metals and where they are mined #Palladium SPONSOR: New Age Metals $NAM.ca $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN

Posted by AGORACOM-JC at 5:00 PM on Wednesday, March 11th, 2020

SPONSOR: New Age Metals Inc. The company owns one of North America’s largest primary platinum group metals deposit in Sudbury, Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces Inferred. Learn More.

The most expensive metals and where they are mined

  • Palladium is the most expensive of the four major precious metals – gold, silver and platinum being the others.
  • It is rarer than platinum, and is used in larger quantities for catalytic converters.
  • In the near-term, the demand for metals used in catalytic converters is expected to be steady, buoyed by growing automotive sales in Asia.

By Matthew Hall

Palladium

Rhodium’s little brother palladium also did well out of the Dieselgate scandal. After sales of diesel vehicles slumped and petrol alternatives came back into fashion, platinum – used primarily in catalytic converters for diesel vehicles – took a tumble, while petrol-friendly palladium rose.

Palladium is the most expensive of the four major precious metals – gold, silver and platinum being the others. It is rarer than platinum, and is used in larger quantities for catalytic converters. In the near-term, the demand for metals used in catalytic converters is expected to be steady, buoyed by growing automotive sales in Asia. However, the increased uptake of battery-electric vehicles – which do not use catalytic converters – could see palladium demand take a hit.

Russia00n mining company Nornickel is the top global palladium producer, pulling up 86 metric tons of the metal in 2019.

Rhodium

Relatively unknown to the layperson, rhodium is quietly one of the hottest trades right now, after a price surge of more than 30% this year. Rhodium previously peaked – and quickly crashed – in 2008 at more than $10,000 per troy ounce (ozt), but the metal is now trading above that 2008 high on the back of a swell in demand from the automotive industry.

Rhodium is used in catalytic converters, a part of vehicle exhaust systems that reduce toxic gas emissions and pollutants. According to S&P Global Platts, almost 80% of demand for rhodium and palladium comes from the global automotive industry. Fortunately for South Africa at least, around 80% of all rhodium is mined within its borders.

Part of the reason for the metal’s price leap is its rarity. Annual rhodium production sits at around 30 tonnes – to place that in context, gold miners annually dig up between 2,500 and 3,000 tonnes of the precious metal. Rhodium also benefitted from the Volkswagen emissions scandal, or Dieselgate, the 2015 emissions scandal that rocked the automotive industry. With major economies including China and India tightening emissions rules, platinum group metals (PGM) miners are anticipating good times ahead for rhodium.

Gold

Part durability, part tradition, gold is among the most versatile commodities. Primarily used in jewellery, but also having significant applications across electronics and aerospace due to its durability and conductivity, gold is, to put it plainly, everywhere.

Source: https://www.mining-technology.com/features/five-most-expensive-metals-and-where-they-are-mined/

CLIENT FEATURE: Mota Ventures MOTA.ca – $29,000,000 in Combined Sales with 2019 EBITDA of Approximately 12.5% $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:53 PM on Wednesday, March 11th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

MOTA:CSE

RECENT HIGHLIGHTS

  • Direct to Consumer E-commerce retailer
  • Revenue generating, EBIDTA positive
  • Formalized Joint Venture With Bevcanna Enterprises: Read More
    • Will share equal ownership in the Joint Venture and will be jointly responsible for developing and funding its operations
    • Company will provide manufacturing, marketing and distribution infrastructure in the European market.
    • Parties have determined an initial product launch and will provide further details on specific regions and timing once finalize
  • Announced Collaboration for Sativida US Expansion Read More 
    • Unified Funding will provide assistance to Sativida with product sourcing, packaging, shipping, payment infrastructure and marketing
    • Sativida has become the number one search-ranked online retailer of CBD products in Spain and Mexico
  • Entered into Licensing Agreement with Phenome One Read More
    • A privately held full-service live genetic and seed preservation cannabis company.
    • Mota will have full access to Canada’s largest live genetic cannabis library with over 350 cultivars
    • Mota will have the right to propagate, cultivate, harvest and process a minimum of 10 selected cultivars

2 World Class Brands

#1. FIRST CLASS CBD

ONE OF THE LARGEST US BASED ONLINE RETAILERS OF CBD PRODUCTS

HIGHLIGHTS:

  • Leader in online CBD sales in North America
  • Crop to package model: US grown CBD hemp
  • Acquired at a 1.5 times revenue valuation
  • Current customer base 142,000 customers -with additional leads of over 424,000 potential new customers
  • 2019 Sales of $19.2M USD/ EBITDA of 2.7M USD

  #2. SATIVIDA

ONLINE DIRECT TO CONSUMER RETAILER OF A VAST RANGE OF ORGANICE CBD OILS AND COSMETICS

HIGHLIGHTS:

  • Current distributor of CBD products in Spain, Portugal, Austria, Germany, France and the United Kingdom
  • Number one search-ranked online retailer in Spain and Mexico
  • Award winning product line known for its minimal heavy metal content and accurate CBD levels
  • 100% organic products

 FIND OUT MORE!

Hub on Agoracom

FULL DISCLOSURE: Mota Ventures. is an advertising client of AGORA Internet Relations Corp.

Hollister Biosciences $HOLL.ca Enters Letter of Intent to Acquire Alphamind $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca Brands

Posted by AGORACOM-JC at 7:02 AM on Wednesday, March 11th, 2020
  • Entered into a letter of intent on March 9th, 2020 to acquire Alphamind Brands
  • Company developing legal mushroom based natural health products and conducting R&D in conjunction with accredited universities to develop psilocybin based compounds for drug development
  • All stock purchase price is anticipated to be CDN$ 1,200,000 with such payment to be made in Hollister common stock

VANCOUVER, March 11, 2020 – Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that the Company has entered into a letter of intent (the “LOI“) on March 9th, 2020 to acquire Alphamind Brands ( “Alphamind“), a company developing legal mushroom based natural health products and conducting R&D in conjunction with accredited universities to develop psilocybin based compounds for drug development.

The all stock purchase price is anticipated to be CDN$ 1,200,000 with such payment to be made in Hollister common stock. The stock price will be determined based on the greater of the 14-day VWAP (Volume Weighted Average Price) subsequent to announcing the transaction and $0.20.  The acquisition is subject to normal course due diligence. 

“We are very pleased to have entered into an LOI to complete this very exciting acquisition”, shared Carl Saling, Founder and CEO of Hollister Biosciences Inc.  “It is a fundamental value of our company to improve the overall health and performance of our customers through our high-quality products and the health benefits associated with medicinal mushrooms are tremendous.  Not to mention, it is our continual objective to broaden our product scope and Alphamind, with its experienced management team, is a perfect foothold for us in the fast-growing market for medicinal mushrooms and complements our existing cannabis and hemp-based product offering.”

“I think we have found a great partner in Hollister”, shared Robert Birmingham, CEO of Alphamind Brands.  “We have medicinal mushroom based product SKU’s ready to ship and R&D is underway to develop an exciting IP portfolio surrounding psilocybin based pharmaceutical treatments. Being under the Hollister umbrella will allow us to access additional markets and leverage their existing manufacturing and distribution infrastructure and will be a fundamental part of the future growth of our business.”

In association with the arm’s length transaction, Hollister will not be assuming any long-term debt and there is no change in Management, or the Board of Directors of Hollister being contemplated at this time.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a diversified cannabis company with multiple, high-quality products now carried in 220 of Indus Holdings (CSE: INDS), Hollister’s exclusive distribution partner’s 600 dispensaries. This level of penetration is expected to grow as the Company accelerates its seed to shelf, high margin business and product development model.

Capitalizing on this success, Hollister’s vision is to become the sought-after premium brand portfolio of innovative, high quality cannabis across multiple states and hemp products nationwide.

Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California, the birthplace of the “American Biker” from which we embrace the outlaw roots of Hollister to drive our Company fearlessly down the road of success.

Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll ranked as California’s #1 hash infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures.

Website: www.hollistercannabisco.com 

About Alphamind Brands

Alphamind Brands is a Canada and US based growth stage company developing a portfolio of legal mushroom based natural health products as well as conducting R&D initiatives, led by Dr. Nikos Apostolopoulos, to explore psilocybin based pharmaceutical treatments.  The company’s “ready to ship” product SKU’s include cordyceps, lion’s mane, chaga and reishi mushroom based: liquid cordyceps, concentrated mushroom powder, tea, chocolate.  The company’s product SKU’s under development include syrups, elixirs, cold beverages and nasal spray.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/hollister-biosciences-enters-letter-of-intent-to-acquire-alphamind-brands-301021154.html

SOURCE Hollister Biosciences Inc.

CBD Market on Course to Grow 400% in Europe Alone SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:08 PM on Tuesday, March 10th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large
  • Over the next five years, the global CBD market is expected to accelerate to $23.6bn, according to Grand View Research and Europe’s CBD market is set to grow by 400%.

The growth of the CBD market in Europe is thanks to the growing adoption of CBD infused products in industries such as pharmaceuticals, personal care, cosmetics, nutraceuticals, along with medical applications.

CBD is seeing monumental demand in Europe. In Europe alone, the market is on course to grow 400% over the next four years, according to the Brightfield Group.

According to New Frontier Data‘s EU CBD Consumer Report: 2019 Overview, 46% of Europeans view CBD favourably, and up to 77% of surveyed respondents also believe CBD should be accessible in some way.

CBD opportunities

The legal cannabis industry continues to expand around the world with major contribution to the market coming from continuous legislative victories in North America and Europe. In particular, legalisation of medical cannabis, and decriminalisation in some countries, has led to a significant decrease in black-market activity, as people are shifting to legally purchasing cannabis for medical as well as recreational use.

In the meantime, local governments reap the benefits through taxation. For instance, the state of California had collected a total of $345.2m in tax revenue from legal cannabis during the first year of regulated sales in 2018. Revenue generated from these taxes encouraged the local governments to fund several development programmes for education and infrastructure.

Medical cannabis

Overall, data by Grand View Research indicates that the medical segment held the dominant revenue share of the cannabis market, accounting for 71.0% in 2019. Medical use of cannabis is strictly categorised as a medicine prescribed by a physician and the distribution of these medicines is regulated by the government. However, by 2027, adult-use is expected to become the fastest-growing segment with adult-use products ranging from a highly potent concentrate to a simple food ingredient.

In recent years, CBD products have swiftly emerged and the growth of the CBD market is largely attributed to various medical applications that are associated with the products. For example, full-spectrum CBD oil is considered to be a great source of Omega 3 and Omega 6; Omega 3 plays a vital role in creating hormones that regulate inflammation as well as contractions and relaxation of arteries.

SOURCE: https://www.healtheuropa.eu/cbd-market-to-grow-400-in-europe/98021/

Tartisan Nickel Corp. $TN.ca Completes Spectral Analysis and SAR Surveys over Sill Lake Lead-Silver Project and Files Assessment Report $ROX.ca $FF.ca $EDG.ca $AGL.ca $ANZ.ca

Posted by AGORACOM-JC at 12:07 PM on Tuesday, March 10th, 2020
Tc logo in black
  • Completed a Spectral Analysis survey and a Synthetic Aperture Radar survey over the Sill Lake Lead-Silver Project, Vankoughnet Township, Ontario
  • The surveys covered all 22 single-cell mining claims as well as the four boundary-cell mining claims owned by the Company’s subsidiary, Canadian Arrow Mines Limited

TORONTO, ON / March 10, 2020 / Tartisan Nickel Corp. (CSE:TN)(OTC:TTSRF)(FSE:A2D) (“Tartisan”, or the “Company”) is pleased to announce that the Company has completed a Spectral Analysis survey and a Synthetic Aperture Radar survey over the Sill Lake Lead-Silver Project, Vankoughnet Township, Ontario. The surveys covered all 22 single-cell mining claims as well as the four boundary-cell mining claims owned by the Company’s subsidiary, Canadian Arrow Mines Limited.

The most abundant minerals on the Sill Lake mining claims were seen to be saponite, a clay mineral from hydrothermal alteration as well as orthoclase feldspar and kaolinite, the hydrothermal alteration product of orthoclase. Principal minerals characteristic of the lead-silver vein were determined to be galena and goethite. Galena is the principal ore mineral of the low-alpha lead on the Sill Lake Project, which goethite is the principal alteration product of sulphides like galena.

As the report notes, “In the centre of the Sill Lake Claims the lead-silver deposit and underground workings are located. The spectral analysis survey outlined a number of minerals spatially associated with the deposit. Using the Target Vector Mineral (“TVM”) overlap technique for the Sill lake Claims a number of areas of where three and four TVM’s overlaps were outlined. One area on the claims outlined a general north-south TVM lead-silver target zone from 65m to 190m wide and approximately 650m in length.”

The anomaly covers the northern trace of the mineralization and is centred on boundary cell mining claim 272137 and single-cell mining claim 297898, with a minor response on claim 206180. Another minor response on claim 204833, when plotted with the others, may suggest a separate structure oriented perpendicular to the principal trend of the Sill Lake lead-silver vein; and along the principal lithological contact between ultramafic intrusive rocks on the north and mafic volcanic rocks to the south, with conformable interbedded sedimentary rocks.

Tartisan CEO Mr. Mark Appleby said, “The survey showed us that there may be much more to the Sill Lake Lead-Silver Project than anyone previously thought. We plan to follow up the anomalies with detailed geological mapping and sampling this summer.”

The Company is pleased with the results of the survey and has requested Aster Funds Ltd to survey and report on the Kenbridge Nickel-Copper-Cobalt Project as well.

About Tartisan Nickel Corp.

Tartisan Nickel Corp. is a Canadian based mineral exploration and development company which owns a 100% stake in the Kenbridge Nickel-Copper Project in Ontario; a 100% interest in the Sill Lake Lead-Silver project, Vankoughnet Township, Ontario; a 100% interest in the Don Pancho Zinc-Lead-Silver Project in Peru just 9 km from Trevali’s Santander mine. Tartisan also owns a 100% stake in the Ichuna Copper-Silver Project, also in Peru, contiguous to Buenaventura’s San Gabriel property. The Company also owns a significant equity stake in Eloro Resources Ltd, which is exploring the low-sulphidation epithermal La Victoria Gold/Silver Project in Ancash, Peru as well as its recently acquired Iska Iska property in Bolivia.

Tartisan Nickel Corp. common shares are listed on the Canadian Securities Exchange (CSE:TN; US-OTC:TTSRF; FSE:A2D). Currently, there are 100,403,550 shares outstanding (103,103 ,550 fully diluted).

For further information, please contact Mr. D. Mark Appleby, President & CEO and a Director of the Company, at 416-804-0280 ([email protected]). Additional information about Tartisan can be found at the Company’s website at www.tartisannickel.com or on SEDAR at www.sedar.com.

Jim Steel MBA P.Geo. is the Qualified Person under NI 43-101 and has read and approved the technical content of this News Release.

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

SOURCE: Tartisan Nickel Corp.

NORTHBUD $NBUD.ca – Legal #pot industry more than doubles contribution to Canada’s #GDP since #legalization: StatsCan $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 4:32 PM on Monday, March 9th, 2020

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

Legal pot industry more than doubles contribution to Canada’s GDP since legalization: StatsCan

  • Canada’s cannabis industry represented $7.24 billion to the country’s gross domestic product in December
  • Illicit cannabis market’s contribution to Canada’s GDP has fallen by over 20 per cent

The country’s legal cannabis market represents $3.0 billion of economic output to Canada’s GDP, an increase of 138 per cent when recreational pot was legalized in Oct. 2018. Meanwhile, the illicit cannabis market’s contribution to Canada’s GDP has fallen by over 20 per cent to about $4.18 billion in that same time.

Source: https://www.bnnbloomberg.ca/cannabis-canada-pot-industry-added-nearly-7-24b-to-gdp-in-august-statscan-says-1.1397728

Healthcare IT #Mhealth Market Worth $511.06 Billion by 2027 SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 1:15 PM on Monday, March 9th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Healthcare IT Market Worth $511.06 Billion by 2027

  • Healthcare IT market is expected to grow at a CAGR of 13.8% from 2019 to reach $511.06 billion by 2027.

London, March 06, 2020 – According to a new market research report “Healthcare IT Market by Product (EMR, mHealth, PHM, RIS, PACS, RCM, Healthcare Analytics, Telehealth, SCM, HIE), Component (Software, Service), Delivery Mode (Web, Cloud) and End User (Hospital, Payer, Pharmacy, Ambulatory, Homecare)- Global Forecast to 2027”, published by Meticulous Research®, the healthcare IT market is expected to grow at a CAGR of 13.8% from 2019 to reach $511.06 billion by 2027.

Health Information Technology (Healthcare IT) is a broad term that defines the technology and infrastructure utilized to record, analyze, and share patient health data in healthcare organizations. The aim of Healthcare IT solutions is to offer better care for patients and help accomplish health equity. It also endorses recording of patient data to improve healthcare delivery and allow for analysis of information for both healthcare practitioners and ministry of health/government agencies.

With increasing pressure to curtail healthcare cost and improve healthcare quality, investments in healthcare IT are gaining traction and are largely driven by the need for savings, economies of scale, and improving cash flow. According to a survey performed by Octopus group, more than 100 global institutional investors have planned to increase their investment in healthcare infrastructure, including health IT, by $200 billion over the next five years. By adopting various healthcare IT solutions such as EHR, PACS, and CPOE among others, healthcare organizations have reduced the operational cost and improved savings along with better patient care. For instance, with increasing adoption of Cerner Dynamic Documentation platform, Northern Light Health (U.S.) saved an estimated $1.3 million annually, by increasing provider efficiency, improving satisfaction with their electronic health record, and streamlining the discharge process. Similarly, by adopting Cerner ITWorks, University of Missouri Health Care (U.S.) reduced the organization’s IV obsolescence rate by more than 43% over three months. In addition, the university also adopted Cerner’s revenue cycle management solutions in 2018.

The healthcare IT solutions market study presents historical market data in terms of value (2017, and 2018), estimated current data (2019), and forecasts for 2027 – by product, component, delivery mode, end-user, and geography. The study also evaluates industry competitors and analyzes their market share at the global and regional level.

Based on product type, the healthcare providers solutions segment accounted for the largest share of the healthcare IT market and is slated to grow faster during the forecast period. The large share of this segment is primarily attributed to the factors such as growing focus on patient safety & care, increasing demand for integrated healthcare solutions, rising investments in development of healthcare infrastructure in emerging countries, increasing number of government initiatives & regulatory mandates on implementing eHealth solutions, increasing demand for quality healthcare, and rising awareness about electronic health records (EHRs). In addition, growing geriatric population & related ailments and patient workload on healthcare systems across the globe are also driving adoption of digitization solutions among healthcare providers.

Based on component type, the services segment held the largest share of the overall healthcare IT market. The largest share of this segment is mainly attributed to the increasing need to reduce healthcare costs, shift towards cloud-based services, rising adoption of digital solutions across healthcare organizations, and growing need to reduce administrative overheads of the healthcare industry.

Based on delivery mode, the overall healthcare IT market is segmented into web/cloud based and on-premises. Web & cloud-based solutions accounted for the largest share of the overall healthcare IT solutions market owing to its benefits such as on lower upfront cost, on-demand self-serving deployment model, excessive storage flexibility, and greater security.

Based on the end user, healthcare providers held the largest share of the overall healthcare IT market and is projected to grow at a fastest CAGR during the forecast period. The largest share of this segment is mainly attributed to rising patient volume, growing awareness about electronic health records (EHRs), growing healthcare spending by the countries across globe, and increasing adoption of healthcare IT solutions by healthcare providers.

The report also includes extensive assessment of the product portfolio, geographic analysis, and key strategic developments adopted by leading market participants in the industry over the past 4 years (2016–2019). The healthcare IT solutions market has witnessed number of new product launches, agreements, partnerships & collaborations, expansions, and acquisitions in the recent years. For instance, in October 2019, Cerner collaborated with ResMed (U.S.) to help providers make more informed treatment decisions, control costs, and deliver seamless care across health systems. Similarly, in July 2019, McKesson opened its new distribution center in Puyallup, Washington, U.S. to serve hospitals, health systems, community pharmacies, and national retail pharmacies across the state of Washington.

The key players operating in the global healthcare IT market are McKesson Corporation (U.S.), Optum Health (U.S.), International Business Machine Corporation (IBM) (U.S.), Allscripts Healthcare Solutions, Inc. (U.S.), athenahealth, Inc. (U.S.), Epic Systems Corporation (U.S.), Dell Technologies Inc. (U.S.), GE Healthcare (U.S.), Cerner Corporation (U.S.), Oracle Corporation (U.S.), Cognizant Technology Solutions Corporation (U.S.), Nuance Communications, Inc. (U.S.), eClinicalWorks (U.S.) NextGen Healthcare, Inc. (U.S.), Computer Programs and Systems, Inc. (CPSI) (U.S.), Conifer Health Solutions, LLC. (U.S.), 3M Company (U.S.), Koninklijke Philips N.V. (The Netherlands), and Infor, Inc. (U.S.) among others.

Source: https://www.globenewswire.com/news-release/2020/03/06/1996384/0/en/Healthcare-IT-Market-Worth-511-06-Billion-by-2027-Exclusive-Report-by-Meticulous-Research.html

Hollister Biosciences $HOLL.ca Signs Definitive Agreement to Acquire Venom Extracts With $16.4 Million in Revenue and $2.48 Million EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 4:48 PM on Friday, March 6th, 2020
  • This highly accretive acquisition will strengthen Hollister’s brand portfolio and broaden its distribution across multiple states
  • For the year ended December 31, 2019, Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges.

VANCOUVER, March 6, 2020 – Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce the Company has entered into a definitive agreement  (the “Agreement“) on March 6th, 2020 to acquire Venom Extracts ( “Venom“), one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.

On February 25, 2020, the Company first announced a Letter of Intent to acquire Venom, including the following financial figures and terms.

HIGHLY ACCRETIVE $20,000,000 ACQUISITION

For the year ended December 31, 2019, Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges. 2019 Revenue and EBITDA for Venom Extracts are as reported by Management. Though Hollister believes the figures to be highly reliable, their audit will be part of the ongoing due diligence before closing.   

The all stock purchase price is anticipated to be CDN$ 20,000,000, with 70% to be paid upfront and 30% to be paid upon milestone achievements related to revenue targets for Venom. The acquisition is expected to close by March 31, 2020 subject to normal course due diligence.

KEY TERMS OF THE AGREEMENT:

  • The Company will acquire Venom Extracts for CDN$20,000,000 with such payment to be issued in Hollister common stock (the “Payment Shares“)
  • The stock price will be determined based on the greater of:
    • The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
  • Once the share price is established, 70% of the Payment Shares will be issued upon closing of the transaction, subject to hold periods
  • The remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021:
    • 20% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 30,000,000 (calculated in accordance with IFRS from January 1, 2020).
    • 10% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 40,000,000(calculated in accordance with IFRS from January 1, 2020).

“We are very pleased to have entered into a definitive agreement to complete this transformational acquisition”, shared Carl Saling, Founder and CEO of Hollister Biosciences, Inc.  “Financially, we are bolting on substantial revenue and EBITDA, while strategically, this allows for the opportunity to bring Venom into the California marketplace and help scale Hollister’s existing operation. Likewise, it allows for the opportunity to introduce Hollister’s products into the Arizona and Nevada marketplaces to start with.” 

“This is an exciting acquisition and we are happy to be taking this critical step toward closing”, shared Jacob Cohen, Founder of Venom Extracts.  “This transaction represents the next step in ensuring the future growth of both Hollister and Venom.  We are looking forward to increasing the geographic scope of our operation by expanding into the California marketplace through Hollister’s existing platform, as well as, exploring expansion of our existing product scope collectively.”

In association with the acquisition, Hollister will not be assuming any long-term debt, a new control position will be created and there is no change in Management, or the Board of Directors of Hollister being contemplated at this time.

Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange.

This press release is available on the Company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a diversified cannabis company with multiple, high-quality products now carried in 220 of Indus Holdings (CSE: INDS), Hollister’s exclusive distribution partner’s 600 dispensaries. This level of penetration is expected to grow as the Company accelerates its seed to shelf, high margin business and product development model.

Capitalizing on this success, Hollister’s vision is to become the sought-after premium brand portfolio of innovative, high quality cannabis across multiple states and hemp products nationwide.

Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California, the birthplace of the “American Biker” from which we embrace the outlaw roots of Hollister to drive our Company fearlessly down the road of success.

Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll ranked as California’s #1 hash infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures.

Website:  www.hollistercannabisco.com 

About Venom Extracts

Venom Extracts is one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.  With an experienced management team and unparalleled reputation for quality, Venom Extracts prides itself as a differentiated extraction company by producing legal Marijuana products at a price point that allows retailers to generate higher profits.  Focused on proprietary efficiencies, the Company is able to produce more product per square foot than its competition, maintaining lower costs and risks than a typical extraction company. The company’s expansion strategy is centered on entering new markets/states that are approved for medical cannabis use and/or approved or have a reasonable expectation to be approved for recreational use in the near future.  

Website:  www.venomextracts.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/hollister-biosciences-signs-definitive-agreement-to-acquire-venom-extracts-with-16-4-million-in-revenue-and-2-48-million-ebitda-301019220.html

SOURCE Hollister Biosciences Inc.